Mirikizumab
16591
Phase 3 small_molecule active
Quick answer
Mirikizumab for Ulcerative Colitis is a Phase 3 program (small_molecule) at Eli Lilly and Company with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Ulcerative Colitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active